Stephen V. Liu, MD - Visual Exploration of the Possibilities for Macrocyclic TKIs in Treatment-Naïve and Pretreated Fusion-Positive NSCLC and Other Tumors - a podcast by PVI, PeerView Institute for Medical Education
from 2022-03-31T18:00
Go online to PeerView.com/BNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the expanding role of macrocyclic TKIs in the treatment of fusion-positive NSCLC and other solid tumors. Upon completion of this activity, participants should be better able to: Discuss the structure and mechanisms of action of macrocyclic tyrosine kinase inhibitors (TKIs) and their role in the treatment of fusion-positive non–small cell lung cancer (NSCLC) and other solid tumors, Compare the characteristics, efficacy, and safety of macrocyclic TKIs with those of standard TKIs in the treatment fusion-positive NSCLC and other solid tumors, including in treatment-naïve and pretreated populations, Implement best practices for identifying patients with fusion-positive NSCLC or other solid tumors who might benefit from the use of macrocyclic TKIs in the context of clinical practice or clinical trials.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education